ES2662948T3 - Adenovirus recombinante para expresar simultáneamente interferón alfa de cerdo e interferón gamma de cerdo - Google Patents
Adenovirus recombinante para expresar simultáneamente interferón alfa de cerdo e interferón gamma de cerdo Download PDFInfo
- Publication number
- ES2662948T3 ES2662948T3 ES13796479.7T ES13796479T ES2662948T3 ES 2662948 T3 ES2662948 T3 ES 2662948T3 ES 13796479 T ES13796479 T ES 13796479T ES 2662948 T3 ES2662948 T3 ES 2662948T3
- Authority
- ES
- Spain
- Prior art keywords
- porcine
- interferon
- nucleotide sequence
- gene
- recombinant adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 47
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 44
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 43
- 102000006992 Interferon-alpha Human genes 0.000 title claims description 40
- 102000008070 Interferon-gamma Human genes 0.000 title description 33
- 229940044627 gamma-interferon Drugs 0.000 title description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims abstract description 29
- 241000700605 Viruses Species 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 17
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims abstract description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229950000038 interferon alfa Drugs 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZDSRFXVZVHSYMA-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 ZDSRFXVZVHSYMA-CMOCDZPBSA-N 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 101710140501 Sulfate adenylyltransferase subunit 2 1 Proteins 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010068794 tyrosyl-tyrosyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120058410A KR101329348B1 (ko) | 2012-05-31 | 2012-05-31 | 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스 |
| KR20120058410 | 2012-05-31 | ||
| PCT/KR2013/004784 WO2013180501A1 (ko) | 2012-05-31 | 2013-05-31 | 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2662948T3 true ES2662948T3 (es) | 2018-04-10 |
Family
ID=49673627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13796479.7T Active ES2662948T3 (es) | 2012-05-31 | 2013-05-31 | Adenovirus recombinante para expresar simultáneamente interferón alfa de cerdo e interferón gamma de cerdo |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2871240B1 (enExample) |
| JP (1) | JP6386448B2 (enExample) |
| KR (1) | KR101329348B1 (enExample) |
| CN (1) | CN104583410B (enExample) |
| ES (1) | ES2662948T3 (enExample) |
| WO (1) | WO2013180501A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107286257A (zh) * | 2017-08-09 | 2017-10-24 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种重组猪长效干扰素α及制备此长效干扰素的融合蛋白及其制备方法 |
| KR102384683B1 (ko) * | 2020-05-07 | 2022-04-11 | 대한민국 | 구제역 바이러스 억제 활성을 갖는 신규한 돼지 인터페론-알파 융합 단백질 및 이의 용도 |
| CN115595312A (zh) * | 2021-06-28 | 2023-01-13 | 中国农业大学（Cn） | 一种重组腺病毒及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8058248B2 (en) * | 2001-04-26 | 2011-11-15 | The United States Of America As Represented By The Secretary Of Agriculture | Foot and mouth disease virus vaccine comprising interferons |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US7632509B2 (en) | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| WO2007059461A2 (en) * | 2005-11-10 | 2007-05-24 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
| US7833533B2 (en) * | 2008-04-24 | 2010-11-16 | The United States Of America As Represented By The Secretary Of Agriculture | Enhanced antiviral activity against foot and mouth disease |
-
2012
- 2012-05-31 KR KR20120058410A patent/KR101329348B1/ko active Active
-
2013
- 2013-05-31 JP JP2015514906A patent/JP6386448B2/ja active Active
- 2013-05-31 CN CN201380029029.6A patent/CN104583410B/zh active Active
- 2013-05-31 EP EP13796479.7A patent/EP2871240B1/en active Active
- 2013-05-31 ES ES13796479.7T patent/ES2662948T3/es active Active
- 2013-05-31 WO PCT/KR2013/004784 patent/WO2013180501A1/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015523858A (ja) | 2015-08-20 |
| WO2013180501A1 (ko) | 2013-12-05 |
| EP2871240A4 (en) | 2016-01-27 |
| EP2871240A1 (en) | 2015-05-13 |
| EP2871240B1 (en) | 2017-12-20 |
| CN104583410A (zh) | 2015-04-29 |
| KR101329348B1 (ko) | 2013-11-15 |
| CN104583410B (zh) | 2017-09-22 |
| JP6386448B2 (ja) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7731974B2 (en) | Mutant vesicular stomatitis viruses and uses thereof | |
| Ashraf et al. | Spring viraemia of carp virus: recent advances | |
| Kelly et al. | Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting | |
| Tafalla et al. | In vitro and in vivo differential expression of rainbow trout (Oncorhynchus mykiss) Mx isoforms in response to viral haemorrhagic septicaemia virus (VHSV) G gene, poly I: C and VHSV | |
| Chen et al. | The antiviral defense mechanisms in mandarin fish induced by DNA vaccination against a rhabdovirus | |
| Espín-Palazón et al. | TNFα impairs rhabdoviral clearance by inhibiting the host autophagic antiviral response | |
| JP2007524363A (ja) | 変異体水疱性口内炎ウイルスおよびそれらの使用 | |
| RU2628690C2 (ru) | Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний | |
| TW200936159A (en) | Attenuated oncolytic paramyxoviruses encoding avian cytokines | |
| Yan et al. | Production of transgenic pigs over-expressing the antiviral gene Mx1 | |
| Godahewa et al. | Analysis of complete genome and pathogenicity studies of the spring viremia of carp virus isolated from common carp (Cyprinus carpio carpio) and largemouth bass (Micropterus salmoides): An indication of SVC disease threat in Korea | |
| Wang et al. | Recombinant rabies virus expressing IFNα1 enhanced immune responses resulting in its attenuation and stronger immunogenicity | |
| WO2019191070A1 (en) | Recombinant viral vector and uses thereof | |
| Xia et al. | Identification and characterization of a type I interferon induced by cyprinid herpesvirus 2 infection in crucian carp Carassius auratus gibelio | |
| BR112020009907A2 (pt) | composições e métodos para melhorar produção, crescimento, disseminação, ou eficácia oncolítica e imunoterapêutica de vírus sensíveis a interferon | |
| EP2871240B1 (en) | Recombinant adenovirus for simultaneously expressing pig interferon alpha and pig interferon gamma | |
| KR20180112269A (ko) | Vhsv 백신 및 아쥬반트를 함유하는 백신 조성물 | |
| Pu et al. | Synergism of co-mutation of two amino acid residues in NS1 protein increases the pathogenicity of influenza virus in mice | |
| del Mar Ortega-Villaizan et al. | The application of plasmid DNA constructs encoding antiviral proteins as potential therapeutics against viral infections in salmonid aquaculture | |
| Liang et al. | The distribution of different virulence grass carp reovirus strains in some neglected tissues | |
| Martinez-Lopez et al. | Increasing versatility of the DNA vaccines through modification of the subcellular location of plasmid-encoded antigen expression in the in vivo transfected cells | |
| WO2018067165A1 (en) | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer | |
| Lan et al. | Stability of canine distemper virus (CDV) after 20 passages in Vero-DST cells expressing the receptor protein for CDV | |
| Rice | Investigating pathogenicity of Spring Viraemia of Carp virus (SVCV) and the development of diagnostic tools | |
| CN103865890A (zh) | 一种用于预防病毒性心肌炎的重组病毒及其疫苗和应用 |